Pluripotent hematopoietic stem cells (HSC) are critical in sustaining and constantly renewing the blood and immune system. The ability to alter biological characteristics of HSC by introducing and ...
MIAMI--(BUSINESS WIRE)--OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic ...
ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research, LLC and Transcell Oncologics, LLC have entered into a partnership with the purpose of marketing and the distribution of Transcell Oncologics, LLC Trans ...
Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center. Background: Use of immunohistochemistry (IHC) can increase the detection of ...
TEL AVIV, Israel and WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology ...
Th1+ and Thy1- stem cells expressing CD49f are capable of long-term, multilineage engraftment in mice. Scientists claim to have identified markers that enable the segregation of rare, truly ...
A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the expense of the most primitive pluripotent HSCs.
A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the expense of the most primitive pluripotent HSCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results